PREDICT: Prediction of Response to Depression Interventions using Clinical and TD-fNIRS measurements (Los Angeles, CA)

Sponsor: Kernel

Principal Investigator: Katherine Perdue, PhD

The Prediction of Response to Depression Interventions using Clinical and TD-fNIRS measurements (“PREDICT”) study uses a new type of non-invasive neuroimaging device called the Flow2 by Kernel, which is based on functional Near Infrared Spectroscopy (fNIRS) technology. The PREDICT study aims to recruit up to 450 individuals suffering from Major Depressive Disorder across multiple sites in California who are planning on undergoing one of 3 specific treatments at Bespoke Treatment: Transcranial Magnetic Stimulation, IV Ketamine, or Spravato esketamine.

The purpose of this study is to use Kernel’s brain imaging system, Flow2, to learn more about how patients with depression respond before, during, and after treatment. Our goal is to collect data to support predicting optimal depression treatments for an individual patient.

Participants will have their brains scanned before treatment, after their first treatment, and 24 hours after their treatment course ends. Interested participants must contact our office before they start TMS Therapy, Spravato, or IV Ketamine to enroll in the study, otherwise they will not eligible to participate.

Participants will be paid $75 for participation at our Santa Monica/West LA office, and will receive images of their brain upon study completion. Contact us today to learn more.

For media inquiries or further information, please contact:



Are you looking for TMS & Brain Health?

You’re in the right place! We’ve changed our name and branding to emphasize our commitment to personalized mental healthcare.

Welcome to Bespoke Treatment.